Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test

Journal of Clinical Microbiology

Volumn 44, Issue 9, 2006, Pages 3122-3129

  Van Hamont, Dennis ^a   Van Ham, Maaike A P C ^a   Bakkers, Judith M J E ^a   Massuger, Leon F A G ^a   Melchers, Willem J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE; PRIMER DNA;

ACCURACY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME IMMUNOASSAY; EVALUATION; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPRODUCIBILITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS CARCINOGENESIS; VIRUS CHARACTERIZATION; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS; ANALYTICAL EQUIPMENT; CLASSIFICATION; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; NUCLEIC ACID HYBRIDIZATION; PAPILLOMA VIRUS; UTERINE CERVIX; VAGINA SMEAR; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

CERVIX UTERI; DNA PRIMERS; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; VAGINAL SMEARS;

EID: 33748805525     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00517-06     Document Type: Article

References (37)

1. The ALTS Group. 2000. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J. Natl. Cancer Inst. 92:397-402.
2. Bachtiary, B., A. Obermair, B. Dreier, P. Birner, G. Breitenecker, T. H. Knocke, E. Selzer, and R. Potter. 2002. Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. Int. J. Cancer 102:237-243.
3. Baseman, J. G., and L. A. Koutsky. 2005. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32(Suppl. 1):S16-S24.
4. Bleeker, M. C., C. J. Hogewoning, J. Berkhof, F. J. Voorhorst, A. T. Hesselink, P. M. van Diemen, A. J. van den Brule, P. J. Snijders, and C. J. Meyer. 2005. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin. Infect. Dis. 41:612-620.
5. Castle, P. E., M. Schiffman, R. D. Burk, S. Wacholder, A. Hildesheim, R. Herrero, M. C. Bratti, M. E. Sherman, and A. Lorincz. 2002. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomark. Prev. 11:1394-1399.
6. Castle, P. E., D. Solomon, M. Schiffman, and C. M. Wheeler. 2005. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst. 97:1066-1071.
7. Castle, P. E., C. M. Wheeler, D. Solomon, M. Schiffman, and C. L. Peyton. 2004. Intel-laboratory reliability of Hybrid Capture 2. Am. J. Clin. Pathol. 122:238-245.
8. Clifford, G. M., S. Gallus, R. Herrero, N. Munoz, P. J. Snijders, S. Vaccarella, P. T. Anh, C. Ferreccio, N. T. Hieu, E. Matos, M. Molano, R. Rajkumar, G. Ronco, S. de Sanjose, H. R. Shin, S. Sukvirach, J. O. Thomas, S. Tunsakul, C. J. Meijer, and S. Franceschi. 2005. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366:991-998.
9. Cuschieri, K. S., H. A. Cubie, M. W. Whitley, G. Gilkison, M. J. Arends, C. Graham, and E. McGoogan. 2005. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J. Clin. Pathol. 58:946-950.
10. Cuschieri, K. S., M. J. Whitley, and H. A. Cubie. 2004. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J. Med. Virol. 73:65-70.
11. Cuzick, J., G. Terry, L. Ho, T. Hollingworth, and M. Anderson. 1994. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br. J. Cancer 69:167-171.
12. Goncalves, M. A., E. Massad, M. N. Burattini, and L. L. Villa. 1999. Relationship between human papillomavirus (HPV) genotyping and genital neoplasia in HIV-positive patients of Santos City, Sao Paulo, Brazil. Int. J. STD AIDS 10:803-807.
13. Gravitt, P. E., C. L. Peyton, T. Q. Alessi, C. M. Wheeler, F. Coutlee, A. Hildesheim, M. H. Schiffman, D. R. Scott, and R. J. Apple. 2000. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38:357-361.
14. Harper, D. M., E. L. Franco, C. Wheeler, D. G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, N. S. De Carvalho, C. M. Roteli-Martins, J. Teixeira, M. M. Blatter, A. P. Korn, W. Quint, and G. Dubin. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765.
15. Kleter, B., L. J. van Doorn, L. Schrauwen, A. Molijn, S. Sastrowijoto, J. ter Schegget, J. Lindeman, B. ter Harmsel, M. Burger, and W. Quint. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37:2508-2517.
16. Kleter, B., L. J. van Doorn, J. ter Schegget, L. Schrauwen, K. van Krimpen, M. Burger, B. ter Harmsel, and W. Quint. 1998. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 153:1731-1739.
17. Kornegay, J. R., M. Roger, P. O. Davies, A. P. Shepard, N. A. Guerrero, B. Lloveras, D. Evans, and F. Coutlee. 2003. International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement. J. Clin. Microbiol. 41:1080-1086.
18. Kornegay, J. R., A. P. Shepard, C. Hankins, E. Franco, N. Lapointe, H. Richardson, and F. Coutlee. 2001. Nonisotopic detection of human papillomavirus DNA in clinical specimens using a consensus PCR and a generic probe mix in an enzyme-linked immunosorbent assay format. J. Clin. Microbiol. 39:3530-3536.
19. Koutsky, L. A., K. A. Ault, C. M. Wheeler, D. R. Brown, E. Barr, F. B. Alvarez, L. M. Chiacchierini, and K. U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-1651.
20. Lee, K. R., R. Ashfaq, G. G. Birdsong, M. E. Corkill, K. M. McIntosh, and S. L. Inhorn. 1997. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet. Gynecol. 90:278-284.
21. Levi, J. E., B. Kleter, W. G. Quint, M. C. Fink, C. L. Canto, R. Matsubara, I. Linhares, A. Segurado, B. Vanderborght, J. E. Neto, and L. J. van Doorn. 2002. High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J. Clin. Microbiol. 40:3341-3345.
22. Mahdavi, A., and B. J. Monk. 2005. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 10:528-538.
23. McAdam, A. J. 2000. Discrepant analysis: how can we test a test? J. Clin. Microbiol. 38:2027-2029.
24. Meijer, C. J., P. J. Snijders, and A. J. van den Brule. 2000. Screening for cervical cancer: should we test for infection with high-risk HPV? CMAJ 163:535-538.
25. Melchers, W. J., J. M. Bakkers, J. Wang, P. C. de Wilde, H. Boonstra, W. G. Quint, and A. G. Hanselaar. 1999. Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up. Am. J. Pathol. 155:1473-1478.
26. Molijn, A., B. Kleter, W. Quint, and L. J. van Doorn. 2005. Molecular diagnosis of human papillomavirus (HPV) infections. J. Clin. Virol. 32(Suppl. 1):S43-S51.
27. Munoz, N., F. X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snijders, and C. J. Meijer. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
28. Nobbenhuis, M. A., T. J. Helmerhorst, A. J. van den Brule, L. Rozendaal, F. J. Voorhorst, P. D. Bezemer, R. H. Verheijen, and C. J. Meijer. 2001. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358:1782-1783.
29. Remmink, A. J., J. M. Walboomers, T. J. Heimerhorst, F. J. Voorhorst, L. Rozendaal, E. K. Risse, C. J. Meijer, and P. Kenemans. 1995. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int. J. Cancer 61:306-311.
30. Schiffman, M., M. J. Khan, D. Solomon, R. Herrero, S. Wacholder, A. Hildesheim, A. C. Rodriguez, M. C. Bratti, C. M. Wheeler, and R. D. Burk. 2005. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J. Natl. Cancer Inst. 97:147-150.
31. Sherman, M. E., M. H. Schiffman, A. T. Lorincz, R. Herrero, M. L. Hutchinson, C. Bratti, D. Zahniser, J. Morales, A. Hildesheim, K. Helgesen, D. Kelly, M. Alfaro, F. Mena, I. Balmaceda, L. Mango, and M. Greenberg. 1997. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer 81:89-97.
32. Snijders, P. J., A. J. van den Brule, and C. J. Meijer. 2003. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J. Pathol. 201:1-6.
33. Steenbergen, R. D., J. de Wilde, S. M. Wilting, A. A. Brink, P. J. Snijders, and C. J. Meijer. 2005. HPV-mediated transformation of the anogenital tract. J. Clin. Virol. 32(Suppl. 1):S25-S33.
34. 10) line probe assay. J. Clin. Microbiol. 40:979-983.
35. van Ham, M. A., J. M. Bakkers, G. K. Harbers, W. G. Quint, L. F. Massuger, and W. J. Melchers. 2005. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J. Clin. Microbiol. 43:2662-2667.
36. Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
37. Wallin, K. L., F. Wiklund, T. Angstrom, F. Bergman, U. Stendahl, G. Wadell, G. Hallmans, and J. Dillner. 1999. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Engl. J. Med. 341:1633-1638.